Overview
Karuna Therapeutics developed KarXT (xanomeline-trospium), a novel muscarinic receptor-based treatment for schizophrenia that received FDA approval in 2024 under the brand name Cobenfy, representing the first new mechanism of action for schizophrenia in decades. Karuna was acquired by Bristol Myers Squibb in 2024 for approximately $14 billion.
More in Neuropharmaceuticals
Latest industry news
Precision Neuroscience Raises $250M to Accelerate Brain-Computer Interface Development
2026-11-01 · Funding
Merge Labs Gets Competition as New Rival Neurotech Startup Enters the Consumer BCI Arena
2026-10-31 · Industry
Neuralink Connects to Grok AI Agent, Enabling ALS Patient to Control AI and Make Calls by Thought Alone
2026-10-30 · Product
Implanted BCIs Still Lack a Shared Safety Rulebook, and the Field Is Running Out of Time to Write One
2026-10-29 · Research
Company details
Category
💊 Neuropharmaceuticals
Location
Boston, USA
Funding
Acquired · Bristol Myers Squibb 2024
Website
www.karunatx.comListed
2026-06-15
Is this your company?
Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.
Claim & upgrade listingAdvertise
Reach neurotech professionals
Newsletter sponsorships, featured listings, and sponsored articles.
View packages →